Atreon Orthopedic receives FDA approval for Rotium Bioresorbable Wick!

Rotium_FDA-01.jpg

Today, Atreon Orthopedics announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Rotium Bioresorbable Wick, which is intended to be used in conjunction with suture anchors for the reattachment of tendon to bone in rotator cuff repairs

Rotium Bioresorbable Wick is a a non-woven, microfiber matrix comprising biodegradable polymer fibers that mimic the extracellular matrix structure. Rotium™ supports cellular infiltration and migration, and facilitates functional tissue regeneration.

RenovoDerm Holds Executive Reimbursement Workshop

RD_LI_content-25.png

On July 25, RenovoDerm held an all-day executive reimbursement workshop led by Kathleen Schaum, President of Kathleen D. Schaum & Assoc., Inc. Ms. Schaum is a nationally recognized wound care reimbursement strategy consultant and educator with nearly 50 years of industry experience. Ms. Schaum led the RenovoDerm team in crafting its reimbursement strategy for the Phoenix Wound Care Matrix, which included coding, coverage, and payment. The seminar also focused on identifying and targeting the most applicable markets for the Phoenix and creating a detailed timeline to achieve a product launch.

The workshop was very successful. After significant dialogue with Ms. Schaum, the RenovoDerm team is now better equipped to effectively earn a strategic reimbursement code, implement a detailed sales and marketing strategy, and utilize valuable resources to maximize the company’s value.

Jed Johnson at the American Society of Pediatric Otolaryngology Annual Seminar

ASPO_logo_RGB-01_vert.png

Jed Johnson, Ph.D. will discuss the pathways (and barriers) to bringing tissue engineered constructs to the bedside. He will explore the role of clinical collaborations, as well as the regulatory challenges with commercialization:

  • Advantages of clinical collaborations: experience, facilities, patient populations
  • Regulatory challenges: synthetic devices, cell-based devices, combination devices
  • Funding challenges: animal studies, ISO 10993 biocompatibility studies, clinical trials
  • Commercialization challenges: reimbursement, sales channels, manufacturing scale-up, cost

RenovoDerm receives FDA approval for Phoenix Wound Matrix!

IMG_4630.jpg
Phoenix Wound Matrix (1).png
IMG_5385+(1).jpeg

Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix, which is a wound care device that accelerates the body’s healing response, facilitates tissue growth and regeneration, reduces scar formation and enhances overall cosmesis.

The Phoenix Wound Matrix is a fully resorbable synthetic graft that closely mimics the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.